Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01918683 · ClinicalTrials.gov registry record · NA
TACE With or Without SBRT as Bridging Therapy for Pre-transplant HCC Patients
A NA study of Hepatocellular Carcinoma, sponsored by Abramson Cancer Center at Penn Medicine.
- Active
- Registry status
- NA
- Development phase
- 40
- Enrollment target
- 3
- Study locations
NCT01918683 is a NA study of Hepatocellular Carcinoma that is active but no longer recruiting, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 40 participants, below the 257-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (84% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT01918683, a NA study of Hepatocellular Carcinoma, is active but no longer recruiting, sponsored by Abramson Cancer Center at Penn Medicine.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 40 participants
- Enrollment target
- 3
- Study locations
Study Summary
This trial is designed to be the initial prospective pilot investigation of the effectiveness of combined SBRT and TACE as bridging therapy for HCC patients awaiting liver transplanation. No prospective clinical trials regarding the combination of TACE and SBRT in pre-transplant population have been performed. We propose the trial be conducted as a pilot clinical trial with the goal of enrolling 40 patients into each arm
Conditions Studied
Interventions
- RADIATION TACE transarterial chemoembolization
- RADIATION stereotatic body radiotherapy (SBRT)
Study Locations (3)
Illinois
- Loyola University Medical Center - Maywood
Oregon
- Oregon Health & Science University - Portland
Pennsylvania
- Abramson Cancer Center of the University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2013-07 |
| Est. Completion | 2027-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01918683
The ClinicalTrials.gov registry entry for NCT01918683 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 257-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (84% lower). The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hepatocellular Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which TACE transarterial chemoembolization is the first listed.
NCT01918683 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Illinois, Oregon, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT01918683 about?
NCT01918683 is a clinical study titled "TACE With or Without SBRT as Bridging Therapy for Pre-transplant HCC Patients". This trial is designed to be the initial prospective pilot investigation of the effectiveness of combined SBRT and TACE as bridging therapy for HCC patients awaiting liver transplanation. No prospective clinical trials regarding the combination of TACE and SBRT in pre-transplant population have been...
What is the current status of trial NCT01918683?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 40 participants. The study started on 2013-07. Estimated completion is 2027-12.
What conditions does trial NCT01918683 study?
This clinical trial studies the following conditions: Hepatocellular Carcinoma.
What interventions are being tested in trial NCT01918683?
The interventions under investigation include: TACE transarterial chemoembolization (RADIATION), stereotatic body radiotherapy (SBRT) (RADIATION).
Who is sponsoring clinical trial NCT01918683?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01918683 being conducted?
This trial has 3 study locations across Illinois, Oregon, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatocellular Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Targeted Navigation in Hepatocellular Carcinoma (HCC)
RECRUITING · NA
-
Y90 Radioembolization Dose Delivery and Radiation Exposure Assessment
RECRUITING · NA
-
HepQuant: Study to Assess the Role of Blood-based Biomarkers and Quantitative MR Imaging for Patients Receiving Radiation Therapy for Liver Cancer
RECRUITING · NA
-
Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers
RECRUITING · NA
-
Psychoeducational Intervention for Patients With Hepatocellular Carcinoma
RECRUITING · NA
-
CEUS vs. AMRI for HCC Detection in Patients With Indeterminate Liver Nodules
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.